Literature DB >> 9135497

Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients.

E H Wanderås1, S D Fosså, S Tretli.   

Abstract

The aim of this study was to evaluate the risk of subsequent non-germ cell cancer (SNGC) among men with germ cell cancer and the significance of radiotherapy and chemotherapy as risk factors. The study group consisted of 2006 male patients treated for germ cell cancer at the Norwegian Radium Hospital from 1952 to 1990 with a mean follow-up of 12.5 years. A group of 1194 patients had received radiotherapy only, 346 patients chemotherapy only (mainly cisplatin-based), 277 patients both radiotherapy and chemotherapy (mainly cyclophosphaoffe and doxorubicin-based), and 189 patients no cytotoxic treatment. A total number of 153 SNGCs were diagnosed after a mean interval of 15.9 years. The RR was 1.65 (95% confidence interval (CI), 1.4-1.9), and the mean cumulative risk after 15 years 7.8% (95% CI, 6.2-9.5%). Significantly elevated RRs were found for gastrointestinal cancer combined, cancer of stomach, liver and biliary system, lung, melanoma, bladder and sarcoma. Significantly elevated RRs were found in patients who had received radiotherapy (with or without chemotherapy), and the trend increased with very long follow-up. Patients given both radiotherapy and chemotherapy experienced the highest risk (RR = 3.54; 95% CI, 2.0-5.8), probably due to a high cumulative dose of cytotoxic treatment. Modern chemotherapy did not seem to increase the risk of SNGC, although this study's size and follow-up period did not allow definite conclusions as regards this risk factor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135497     DOI: 10.1016/s0959-8049(96)00458-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

1.  Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

2.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

Authors:  Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 3.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

4.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.

Authors:  Chunkit Fung; Sophie D Fossa; Michael T Milano; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 5.  Clinical stage I seminoma: the case for surveillance.

Authors:  Nathan Lawrentschuk; Neil Fleshner
Journal:  World J Urol       Date:  2009-06-11       Impact factor: 4.226

6.  Efficacy of routine follow-up after first-line treatment for testicular cancer.

Authors:  J R Spermon; J A Witjes; L A L M Kiemeney
Journal:  World J Urol       Date:  2004-09-21       Impact factor: 4.226

Review 7.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  [Diagnostics and treatment of seminomatous germ cell tumors].

Authors:  F Zengerling; J Müller; S Krege; M Schrader
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

Review 9.  [Clinical stage I seminoma. Is surveillance a new therapy standard?].

Authors:  F Zengerling; J Müller; A J Schrader; M Schrader
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

10.  Monte Carlo study on the secondary cancer risk estimations for patients undergoing prostate radiotherapy: A humanoid phantom study.

Authors:  Amir Ghasemi-Jangjoo; Hosein Ghiasi
Journal:  Rep Pract Oncol Radiother       Date:  2020-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.